DNA methylation in early neoplasia

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 101-111

  Carmona, F Javier ^a   Esteller, Manel ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

biomarker; cancer; DNA methylation; early detection; screening

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DNA; MICRORNA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; WNT PROTEIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL HYPERPLASIA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CPG ISLAND; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA METHYLATION; EARLY CANCER; EARLY DIAGNOSIS; EPIGENETICS; GALLBLADDER CARCINOMA; GENE MAPPING; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; MELANOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SIGNAL TRANSDUCTION;

CARCINOMA IN SITU; DNA METHYLATION; EARLY DETECTION OF CANCER; HUMANS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS;

EID: 82955193301     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0184     Document Type: Article

References (105)

1. A. Bird, DNA methylation patterns and epigenetic memory, Genes and development 16(1) (2002), 6-21.
2. M. Esteller, Epigenetics in cancer, The New England journal of medicine 358(11) (2008), 1148-1159.
3. A. P. Feinberg and B. Tycko, The history of cancer epigenetic , Nature reviews 4(2) (2004), 143-153.
4. R. Jaenisch and A. Bird, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals, Nature genetics 33 (2003), 245-254.
5. A. Lujambio and M. Esteller, CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell cycle (Georgetown, Tex 6(12) (2007), 1455-1459.
6. Y. Saito and P. A. Jones, Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell cycle Georgetown, Tex 5(19) (2006), 2220-2222.
7. M. Esteller, Cancer epigenomics: DNA methylomes and histone-modification maps, Nat Rev Genet 8(4) (2007), 286-298.
8. S. B. Baylin and J. E. Ohm, Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature reviews 6(2) (2006), 107-116.
9. Y. Kondo and J. P. Issa, Epigenetic changes in colorectal cancer, Cancer metastasis reviews 23(1-2) (2004), 29-39.
10. S. Lee, K. S. Hwang, H. J. Lee, J. S. Kim and G. H. Kang, Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia, Laboratory investigation; a journal of technical methods and pathology 84(7) (2004), 884-893.
11. M. Esteller, M. F. Fraga,M. Guo et al. , DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis, Human molecular genetics 10(26) (2001), 3001-3007.
12. P. Garcia, C. Manterola, J. C. Araya et al. , Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions, Molecular carcinogenesis 48(1) (2009), 79-89.
13. A. Kaneda and A. P. Feinberg, Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk, Cancer research 65(24) (2005), 11236-11240.
14. T. Sakatani, A. Kaneda, C. A. Iacobuzio-Donahue et al. , Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesisin mice, Science New York, NY 307(5717) (2005), 1976-1978.
15. H. Cui, M. Cruz-Correa, F. M. Giardiello et al. , Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science New York, NY 299(5613) (2003) 1753-1755.
16. P. W. Laird, The power and the promise of DNA methylation markers, Nature reviews 3(4) (2003) 253-266.
17. J. F. Costello, M. C. Fruhwald, D. J. Smiraglia et al. , AberrantCpG-island methylation has non-random and tumour-typespecific patterns, Nature genetics 24(2) (2000), 132-138.
18. M. Esteller, P. G. Corn, S. B. Baylin and J. G. Herman, A gene hypermethylation profile of human cancer, Cancer research 61(8) (2001), 3225-3229.
19. F. R. Hirsch, W. A. Franklin, A. F. Gazdar and P. A. Bunn, Jr. , Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology, Clin Cancer Res 7(1) (2001), 5-22.
20. J. L. Mulshine, Clinical issues in the management of early lung cancer, Clin Cancer Res 11(13 Pt 2) (2005), 4993s- 4998s.
21. I. I. Wistuba and A. F. Gazdar, Lung cancer preneoplasia, Annual review of pathology 1 (2006), 331-348.
22. J. A. Tsou, J. A. Hagen, C. L. Carpenter and I. A. Laird- Offringa, DNAmethylation analysis: a powerful new tool for lung cancer diagnosis, Oncogene 21(35) (2002), 5450-5461.
23. P. P. Anglim, T. A. Alonzo and I. A. Laird-Offringa, DNA methylation-based biomarkers for early detection of nonsmall cell lung cancer: an update, Molecular cancer 7 (2008), 81.
24. R. Dammann, C. Li, J. H. Yoon, P. L. Chin, S. Bates and G. P. Pfeifer, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21. 3, Nature genetics 25(3) (2000), 315-319.
25. K. O. Toyooka, S. Toyooka, A. K. Virmani et al. , Loss of expression and aberrant methylation of the CDH13 (Hcadherin) gene in breast and lung carcinomas, Cancer research 61(11) (2001), 4556-4560.
26. A. K. Virmani, A. Rathi and S. Zochbauer-Muller et al. , Promoter methylation and silencing of the retinoic acid receptorbeta gene in lung carcinomas, Journal of the National Cancer Institute 92(16) (2000), 1303-1307.
27. S. Zochbauer-Muller, K. M. Fong, A. K. Virmani, J. Geradts, A. F. Gazdar and J. D. Minna, Aberrant promoter methylation of multiple genes in non-small cell lung cancers, Cancer research 61(1) (2001), 249-255.
28. D. G. Burbee, E. Forgacs, S. Zochbauer-Muller et al. , Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, Journal of the National Cancer Institute 93(9) (2001), 691-699.
29. S. Toyooka, K. O. Toyooka, R. Maruyama et al. , DNAmethylation profiles of lung tumors, Molecular cancer therapeutics 1(1) (2001), 61-67.
30. S. Zochbauer-Muller, K. M. Fong, A. Maitra et al. , 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer, Cancer research 61(9) (2001) 3581-3585.
31. R. Dammann, T. Takahashi and G. P. Pfeifer, The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas, Oncogene 20(27) (2001), 3563-3567.
32. S. A. Belinsky, K. J. Nikula, W. A. Palmisano et al. , Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proceedingsof the National Academy of Sciences of the United States of America 95(20) (1998), 11891-11896.
33. A. Merlo, J. G. Herman, L. Mao et al. , 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers, Nature medicine 1(7) (1995), 686-692.
34. D. J. Wong, S. A. Foster, D. A. Galloway and B. J. Reid, Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest, Molecular and Cellular Biology 19(8) (1999), 5642-5651.
35. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S. B. Baylin and J. G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer research 59(1) (1999), 67-70.
36. S. A. Ahrendt, J. T. Chow, L. H. Xu et al. , Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer, Journal of the National Cancer Institute 91(4) (1999), 332-339.
37. S. Zochbauer-Muller, S. Lam, S. Toyooka et al. , Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers, International journal of cancer 107(4) (2003), 612-616.
38. S. A. Belinsky,W. A. Palmisano, F. D. Gilliland et al. , Aberrantpromoter methylation in bronchial pithelium and sputum from current and former smokers, Cancer research 62(8) (2002), 2370-2377.
39. S. A. Belinsky, M. J. Grimes, E. Casas et al. , Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum, British journal of cancer 96(8) (2007), 1278-1283.
40. N. Shivapurkar, V. Stastny, M. Suzuki et al. , Application of a methylation gene panel by quantitative PCR for lung cancers, Cancer letters 247(1) (2007), 56-71.
41. J. C. Soria, M. Rodriguez, D. D. Liu, J. J. Lee, W. K. Hong and L. Mao, Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers, Cancer research 62(2) (2002), 351-355.
42. M. Tessema, Y. Y. Yu, C. A. Stidley et al. , Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers, Carcinogenesis 30(7) (2009), 1132-1138.
43. S. Honorio, A. Agathanggelou, M. Schuermann et al. , Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients, Oncogene 22(1) (2003), 147-150.
44. K. Eguchi, Y. Kanai, K. Kobayashi and S. Hirohashi, DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history, Cancer research 57(21) (1997), 4913-4915.
45. J. Brabender, H. Usadel, K. D. Danenberg et al. , Adenomatous polyposis coli gene promoter hypermethylation in nonsmall cell lung cancer is associated with survival, Oncogene 20(27) (2001), 3528-3532.
46. H. J. Grote, V. Schmiemann, S. Kiel et al. , Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer, International journal of cancer 110(5) (2004), 751-755.
47. M. Yoshino, M. Suzuki, L. Tian et al. , Promoter hypermethylation of the p16 andWif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers, International journal of oncology 35(5) (2009), 1201-1209.
48. N. Yanagawa, G. Tamura, H. Oizumi, N. Takahashi, Y. Shimazaki and T. Motoyama, Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers, Cancer science 94(7) (2003), 589-592.
49. D. S. Shames, L. Girard, B. Gao et al. , A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies, PLoS medicine 3(12) (2006), e486.
50. T. Rauch, Z. Wang, X. Zhang et al. , Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay, Proceedings of the National Academy of Sciences of theUnited States of America 104(13) (2007), 5527-5532.
51. J. J. Wong, N. J. Hawkins and R. L. Ward, Colorectal cancer: a model for epigenetic tumorigenesis, Gut 56(1) (2007), 140-148.
52. A. P. Feinberg and B. Vogelstein, Hypomethylation distinguishes genes of some human cancers from their normal counterparts, Nature 301(5895) (1983), 89-92.
53. K. Woodson, A. Flood, L. Green et al. , Loss of insulinlike growth factor-II imprinting and the presence of screendetected colorectal adenomas in women, J Natl Cancer Inst 96(5) (2004), 407-410.
54. F. Sato, N. Harpaz, D. Shibata et al. , Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis, Cancer research 62(4) (2002), 1148-1151.
55. T. Moriyama, T. Matsumoto, S. Nakamura et al. , Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis, Diseases of the colon and rectum 50(9) (2007), 1384-1392.
56. H. Z. Zou, B. M. Yu, Z. W. Wang et al. , Detection of aberrant p16 methylation in the serum of colorectal cancer patients, Clin Cancer Res 8(1) (2002), 188-191.
57. K. Krtolica, M. Krajnovic, S. Usaj-Knezevic, D. Babic, D. Jovanovic and B. Dimitrijevic, Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value, World J Gastroenterol 13(8) (2007), 1187-1194.
58. G. Jie, S. Zhixiang, S. Lei, L. Hesheng and T. Xiaojun, Relationship between expression and methylation status of p16INK4a and the proliferative activity of different areas' tumour cells in human colorectal cancer, International journal of clinical practice 61(9) (2007), 1523-1529.
59. M. O. Hiltunen, L. Alhonen, J. Koistinaho et al. , Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma, International journal of cancer 70(6) (1997), 644-648.
60. B. B. Lee, E. J. Lee, E. H. Jung et al. , Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer, Clin Cancer Res 15(19) (2009), 6185-6191.
61. F. Mittag, D. Kuester,M. Vieth et al. , DAPKpromotormethylation is an early event in colorectal carcinogenesis, Cancer letters 240(1) (2006), 69-75.
62. W. M. Grady, A. Rajput, J. D. Lutterbaugh and S. D. Markowitz, Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer, Cancer research 61(3) (2001), 900-902.
63. L. Shen, Y. Kondo, G. L. Rosner et al. , MGMT promoter methylation and field defect in sporadic colorectal cancer, Journal of the National Cancer Institute 97(18) (2005), 1330-1338.
64. S. M. Dong, E. J. Lee, E. S. Jeon, C. K. Park and K. M. Kim, Progressive methylation during the serrated neoplasia pathway of the colorectum, Mod Pathol 18(2) (2005), 170-178.
65. H. Nakayama, K. Hibi, M. Taguchi et al. ,Molecular detection of p16 promotermethylation in the serum of colorectal cancer patients, Cancer letters 188(1-2) (2002), 115-119.
66. S. Yamaguchi, T. Asao, J. Nakamura,M. Ide and H. Kuwano, High frequency ofDAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum, Cancer letters 194(1) (2003), 99-105.
67. R. Grutzmann, B. Molnar, C. Pilarsky et al. , Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay, PloS one 3(11) (2008), e3759.
68. T. deVos, R. Tetzner, F. Model et al. , Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer, Clinical chemistry 55(7) (2009), 1337-1346.
69. C. Lofton-Day, F. Model, T. Devos et al. , DNA methylation biomarkers for blood-based colorectal cancer screening, Clinical chemistry 54(2) (2008), 414-423.
70. V. Melotte, M. H. Lentjes, S. M. van den Bosch et al. , N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer, Journal of the National Cancer Institute 101(13) (2009), 916-927.
71. T. Nagasaka, N. Tanaka, H. M. Cullings et al. , Analysis of fecal DNA methylation to detect gastrointestinal neoplasia, Journal of the National Cancer Institute 101(18) (2009), 1244-1258.
72. H. M. Muller, M. Oberwalder, H. Fiegl et al. , Methylation changes in faecalDNA: amarker for colorectal cancer screening? Lancet 363(9417) (2004), 1283-1285.
73. Z. H. Huang, L. H. Li, F. Yang and J. F. Wang, Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions, World J Gastroenterol 13(6) (2007), 950-954.
74. M. Oberwalder, M. Zitt, C. Wontner et al. , SFRP2 methylation in fecal DNA - a marker for colorectal polyps, International journal of colorectal disease 23(1) (2008), 15-19.
75. D. A. Ahlquist, Next-generation stool DNA testing: expanding the scope, Gastroenterology 136(7) (2009), 2068-2073.
76. V. V. Levenson, Biomarkers for early detection of breast cancer: what, when, and where? Biochimica et biophysica acta 1770(6) (2007), 847-856.
77. E. Evron, W. C. Dooley, C. B. Umbricht et al. , Detection of breast cancer cells in ductal lavage fluid by methylationspecific PCR, Lancet 357(9265) (2001), 1335-1336.
78. C. Jeronimo, I. Costa, M. C. Martins et al. , Detection of gene promoter hypermethylation in fine needle washings from breast lesions, Clin Cancer Res 9(9) (2003), 3413-3417.
79. R. Krassenstein, E. Sauter, E. Dulaimi et al. , Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation, Clin Cancer Res 10(1 Pt 1) (2004), 28-32.
80. H. Suzuki,M. Toyota, H. Carraway et al. , Frequent epigenetic inactivation ofWnt antagonist genes in breast cancer, British journal of cancer 98(6) (2008), 1147-1156.
81. J. Veeck, E. Noetzel, N. Bektas et al. , Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer, Molecular cancer 7 (2008), 83.
82. K. Miyamoto, T. Fukutomi, S. Akashi-Tanaka et al. , Identification of 20 genes aberrantly methylated in human breast cancers, International journal of cancer 116(3) (2005), 407-414.
83. J. M. Ordway, M. A. Budiman, Y. Korshunova et al. , Identification of novel high-frequency DNA methylation changes in breast cancer, PloS one 2(12) (2007), e1314.
84. S. Tommasi, D. L. Karm, X. Wu, Y. Yen and G. P. Pfeifer, Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer, Breast Cancer Res 11(1) (2009), R14.
85. N. Sato, N. Fukushima, A. Maitra et al. , Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays, Cancer research 63(13) (2003), 3735-3742.
86. N. Hanoun, Y. Delpu, A. A. Suriawinata et al. , The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis, Clinical chemistry 56(7), 1107-1118.
87. T. Liggett, A. Melnikov, Q. L. Yi et al. , Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis, Cancer 116(7), 1674-1680.
88. H. Onay, S. Pehlivan, M. Koyuncuoglu, Z. Kirkali and F. Ozkinay, Multigene methylation analysis of conventional renal cell carcinoma, Urologia internationalis 83(1) (2009), 107-112.
89. R. Henrique, V. L. Costa and C. Jeronimo,Methylation-based biomarkers for early detection of urological cancer, Critical reviews in oncogenesis 13(4) (2007), 265-282.
90. M. Loyo, M. Brait, M. S. Kim et al. , A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma, International Journal of Cancer.
91. MJ. Worsham, K. M. Chen, J. K. Stephen, S. Havard andM. S. Benninger, Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer, Otolaryngol Head Neck Surg 143(1) 116-121, 21, e1-19.
92. Y. Koga, M. Pelizzola, E. Cheng et al. , Genome-wide screen of promoter methylation identifies novel markers in melanoma, Genome research 19(8) (2009), 1462-1470.
93. J. G. Herman and S. B. Baylin, Gene silencing in cancer in association with promoter hypermethylation, N Engl J Med 349(21) (2003), 2042-2054.
94. J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin and S. B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, Proceedings of the NationalAcademy of Sciences of theUnited States of America 93(18) (1996), 9821-9826.
95. J. Zhu and X. Yao, Use of DNA methylation for cancer detection: promises and challenges, The international journal of biochemistry and cell biology 41(1) (2009), 147-154.
96. M. F. Fraga and M. Esteller, DNA methylation: a profile of methods and applications, BioTechniques 33(3) (2002), 632, 4, 6-632, 4,9.
97. B. N. Trinh, T. I. Long and P. W. Laird, DNAmethylation analysis by MethyLight technology. Methods San Diego, Calif 25(4) (2001), 456-462.
98. J. A. Tsou, J. S. Galler, K. D. Siegmund et al. , Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma, Molecular cancer 6(70) (2007).
99. P. P. Anglim, J. S. Galler, M. N. Koss et al. , Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer, Molecular cancer 7(62) (2008).
100. T. Kawasaki, M. Ohnishi, K. Nosho et al. , CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci, Mod Pathol 21(3) (2008), 245-255.
101. D. R. Wang and D. Tang, Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancernoninvasive screening, World J Gastroenterol 14(4) (2008), 524-531.
102. R. J. Shaw, T. Liloglou, S. N. Rogers et al. , Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing, British journal of cancer 94(4) (2006), 561-568.
103. W. Chung, B. Kwabi-Addo, M. Ittmann et al. , Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling, PloS one 3(4) (2008), e2079.
104. S. Beck and V. K. Rakyan, The methylome: approaches for global DNA methylation profiling, Trends Genet 24(5) (2008), 231-237.
105. R. Illingworth, A. Kerr, D. Desousa et al. , A novel CpG island set identifies tissue-specific methylation at developmental gene loci, PLoS biology 6(1) (2008), e22.